Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07547540 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3971297 in Participants With Heart Failure
A Phase 1 study, sponsored by Eli Lilly and Company.
- Not yet
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07547540 is a Phase 1 study that has not yet begun recruiting, run by Eli Lilly and Company. The registered enrollment target is 90 participants.
The verdict
NCT07547540, a Phase 1 study, has not yet begun recruiting, sponsored by Eli Lilly and Company.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess how well LY3971297 is tolerated and what side effects may occur in participants with heart failure with preserved ejection fraction (HFpEF) and participants with heart failure with reduced ejection fraction (HFrEF). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 2 months and will include 1 inpatient visit lasting approximately 4 days and 5 outpatient visits.
Interventions
- DRUG Placebo
- DRUG LY3971297
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07547540
The ClinicalTrials.gov registry entry for NCT07547540 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07547540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07547540 about?
NCT07547540 is a clinical study titled "A Study of LY3971297 in Participants With Heart Failure". The main purpose of this study is to assess how well LY3971297 is tolerated and what side effects may occur in participants with heart failure with preserved ejection fraction (HFpEF) and participants with heart failure with reduced ejection fraction (HFrEF). Blood tests will be performed to investi...
What is the current status of trial NCT07547540?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-07. Estimated completion is 2027-11.
What interventions are being tested in trial NCT07547540?
The interventions under investigation include: Placebo (DRUG), LY3971297 (DRUG).
Who is sponsoring clinical trial NCT07547540?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.